Patents by Inventor Benjamin Alexander Mayes

Benjamin Alexander Mayes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10238680
    Abstract: Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: March 26, 2019
    Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER
    Inventors: Benjamin Alexander Mayes, Adel M. Moussa, Cyril B. Dousson, Gilles Gosselin, Claire Pierra, David Dukhan
  • Patent number: 10231986
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: March 19, 2019
    Assignee: IDENIX PHARMACEUTICALS LLC
    Inventors: David Dukhan, Christophe Claude Parsy, Gilles Gosselin, Jean-François Griffon, Guillaume Brandt, Cyril B. Dousson, Adel M. Moussa, Benjamin Alexander Mayes, Alistar James Stewart
  • Publication number: 20180258130
    Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Application
    Filed: May 16, 2018
    Publication date: September 13, 2018
    Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART, Gilles GOSSELIN, Christophe Claude PARSY, François-René ALEXANDRE, Jean-François GRIFFON, Dominique SURLERAUX, Cyril B. DOUSSON, Claire PIERRA, Houcine RAHALI
  • Publication number: 20180162898
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4?-OR nucleosides of Formula I: or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z1, Z2, Z3, and Z4 are as defined herein.
    Type: Application
    Filed: December 17, 2014
    Publication date: June 14, 2018
    Applicant: IDENIX PHARMACEUTICALS LLC
    Inventors: David Dukhan, Cyril B. Dousson, Adel M. Moussa, Benjamin Alexander Mayes, James Alistair Stewart
  • Publication number: 20170135990
    Abstract: Provided herein are spray-dried particles comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound and methods of their preparation. Also provided herein are pharmaceutical compositions comprising a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, method of their preparation, and their use for treating or preventing hepatitis C virus infection.
    Type: Application
    Filed: March 4, 2015
    Publication date: May 18, 2017
    Applicant: Idenix Pharmaceuticals LLC
    Inventors: Adel M. Moussa, Benjamin Alexander Mayes, Sindhura Ganga
  • Publication number: 20170066795
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Application
    Filed: March 5, 2015
    Publication date: March 9, 2017
    Applicants: IDENIX PHARMACEUTICALS LLC, Merck Sharp & Dohme Corp.
    Inventors: John Zoltan Sulliva-Bolyai, Benjamin Alexander Mayes, Douglas Lytle Mayers, Xiao-Jian Zhou, Adel M. Moussa, Alistair James Stewart, Sindhura Ganga, Clinton Scott Shultz, Alfred Lee
  • Publication number: 20170066779
    Abstract: Provided herein are crystalline and salt forms of methyl N-{(1R)-2-[(2S)-2-{5-[4-(6-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl} pyrrolidin-2-yl]-3H-benzimidazol-5-yl}thieno[3,2-b]thiophen-3-yl)phenyl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl} carbamate, a Flaviviridae, including hepatitis C, virus inhibitor, pharmaceutical compositions comprising the compound, and processes of preparation thereof. Also provided are methods of its use for the treatment of a Flaviviridae, including HCV, infection in a subject in need thereof.
    Type: Application
    Filed: March 4, 2015
    Publication date: March 9, 2017
    Applicant: IDENIX Pharmaceuticals LLC
    Inventors: Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
  • Publication number: 20160280729
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are nucleoside analogs of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, Z1 Z2, Z3, Z4, V, W, X, Y, Ar, R1 and R2 are as described herein.
    Type: Application
    Filed: November 19, 2014
    Publication date: September 29, 2016
    Applicant: IDENIX PHARMACEUTICALS LLC
    Inventors: Adel M. Moussa, Alistair James Stewart, Benjamin Alexander Mayes
  • Publication number: 20160271162
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-alanine phosphoramidate pronucleotides of 2?-methyl 2?-fluoro guanosine nucleoside which display remarkable efficacy and bioavailability for the treatment of for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof; where W and R are as described herein.
    Type: Application
    Filed: October 30, 2014
    Publication date: September 22, 2016
    Applicant: IDENIX PHARMACUETICALS, LLC
    Inventors: Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
  • Patent number: 9339541
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, the compounds are according to Formula 2001: where PD, Base, RA and RB are as provided herein. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: May 17, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Cyril B. Dousson, Benjamin Alexander Mayes, David Dukhan, Adel M. Moussa, Alistair James Stewart
  • Publication number: 20160113956
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, R1 and R2 are as described herein.
    Type: Application
    Filed: September 25, 2015
    Publication date: April 28, 2016
    Inventors: David DUKHAN, Christophe Claude PARSY, Gilles GOSSELIN, Jean-François GRIFFON, Guillaume BRANDT, Cyril B. DOUSSON, Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
  • Patent number: 9309275
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3?-deoxy nucleoside compounds according to Formula 3001a or 3001b: or a pharmaceutically acceptable salts, solvates, stereoisomeric forms, tautomeric forms, or polymorphic forms thereof, wherein PD, Base1 and Base2 are as provided herein.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: April 12, 2016
    Assignees: IDENIX PHARMACEUTICALS LLC, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ MONTPELLIER 2 SCIENCES ET TECHNIQUES
    Inventors: Alistair James Stewart, Adel M. Moussa, Benjamin Alexander Mayes, Francois-Rene Alexandre, Dominique Surleraux, Christophe Claude Parsy, Claire Pierra, David Dukhan, Gilles Gosselin
  • Publication number: 20160083413
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?-chloro nucleosides according to Formula 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.
    Type: Application
    Filed: October 22, 2015
    Publication date: March 24, 2016
    Inventors: Gilles Gosselin, Christophe Claude Parsy, François-René Alexandre, Houcine Rahali, Jean-François Griffon, Dominique Surleraux, Cyril B. Dousson, Claire Pierra, Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart, David Dukhan
  • Publication number: 20160082030
    Abstract: Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.
    Type: Application
    Filed: November 30, 2015
    Publication date: March 24, 2016
    Inventors: Benjamin Alexander Mayes, Adel M. MOUSSA, Cyril B. DOUSSON, Gilles GOSSELIN, Claire PIERRA, David DUKHAN
  • Publication number: 20160002281
    Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Application
    Filed: September 16, 2015
    Publication date: January 7, 2016
    Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART, Gilles GOSSELIN, Christophe Claude PARSY, François-René ALEXANDRE, Jean-François GRIFFON, Dominique SURLERAUX, Cyril B. DOUSSON, Claire PIERRA, Houcine RAHALI
  • Patent number: 9211300
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are according to Formula 1501: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, PD, RA, RB, RC, L, M and Z are as described herein.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: December 15, 2015
    Assignees: Idenix Pharmaceuticals LLC, Centre National De La Recherche Scientifique, Universite Montpellier 2 Sciences et Techniques
    Inventors: Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart, Gilles Gosselin
  • Patent number: 9192621
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein are compounds according to Formula 1001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, Y, Z, A, RC and RD are as described herein.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: November 24, 2015
    Assignee: IDENIX PHARMACEUTICALS LLC
    Inventors: Benjamin Alexander Mayes, Adel M. Moussa
  • Patent number: 9187515
    Abstract: Provided herein are compounds, methods and pharmaceutical compositions for use in treatment of viral infections, including hepatitis C virus (HCV) infections, in hosts in need thereof. In certain embodiments, the compounds are 2?,4?-fluoro nucleosides according to Formula 1001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, RA, and PD are as described herein. In certain embodiments, 2?,4?-fluoro nucleosides are provided which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: November 17, 2015
    Assignee: IDENIX PHARMACEUTICALS LLC
    Inventors: Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart
  • Patent number: 9109001
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: August 18, 2015
    Assignee: IDENIX PHARMACEUTICALS, INC.
    Inventors: Christophe Claude Parsy, Francois-Rene Alexandre, Cyril B. Dousson, David Dukhan, Claire Pierra, Dominique Surleraux, Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart
  • Publication number: 20150037282
    Abstract: Provided herein are compounds, compositions, and methods for the treatment of viral infections, for example, Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are D-amino acid phosphoramidate halogeno pyrimidine nucleoside analog compounds which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the compounds are of Formula I: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein: PD, X, R1, R2, RA, and RB are as described herein.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 5, 2015
    Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Cyril B. DOUSSON, Gilles GOSSELIN, Claire PIERRA, David DUKHAN